We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) has announced the submission of a new drug application (NDA) to the FDA for approval to market Tykerb (lapatinib ditosylate), in combination with Xeloda (capecitabine), for the treatment of advanced or metastatic HER2-positive breast cancer in women who have received prior therapy.
King Pharmaceuticals and GlaxoSmithKline (GSK) have announced that that the results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) study were presented at the European Association for the Study of Diabetes meeting in Copenhagen, Denmark, and published in the New England Journal of Medicine.
AmpliMed has announced interim results from the ongoing Phase I/II clinical trial of Amplimexon (imexon) in combination with the drug dacarbazine (DTIC) in patients with advanced malignant melanoma.
Pharmion, along with its partner MethylGene, has initiated a Phase II trial with of a histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in patients with relapsed or refractory B-cell lymphomas.
Javelin Pharmaceuticals has presented final results of its U.S. Phase IIB study of Dyloject, a proprietary formulation of diclofenac for injection, tested in 353 patients with moderate-to-severe post-surgical pain.
Cardiome Pharma has announced top-line results from both the 300- and 600-mg dosing groups for its recently completed Phase IIa pilot study of RSD1235 (oral).
Genta announced that results of the company's Phase III trial of Genasense (oblimersen sodium) Injection in patients with advanced melanoma have been published online in the Journal of Clinical Oncology.
Lupin Pharmaceuticals announced that the FDA has granted final approval for its abbreviated new drug application (ANDA) for ceftriaxone injection in 10-gram vials.